← Back to Search

Diagnostic Sensor

LUX-Dx ICM Sensor Data Collection for Heart Failure

N/A
Recruiting
Led By Scott Solomon, MD
Research Sponsored by Boston Scientific Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patient is currently in NYHA Class II or III.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion of approximately 4.5 year
Awards & highlights

Study Summary

This trial is designed to study the feasibility of collecting sensor data from insertable cardiac monitor systems.

Who is the study for?
This trial is for heart failure patients in NYHA Class II or III. Eligible participants must have specific echocardiography findings and elevated BNP/NT-proBNP levels, a recent hospitalization for heart failure, or unscheduled IV therapy within the last year. They should be willing to use an ICM mobile app and not have any other active electronic medical devices implanted.Check my eligibility
What is being tested?
The study aims to collect data from Boston Scientific's investigational insertable cardiac monitor (ICM) system called LUX-Dx in patients with heart failure. The focus is on how well the diagnostic sensors work within this new device.See study design
What are the potential side effects?
While specific side effects are not listed, typical risks of implanting a cardiac monitor may include infection at the insertion site, bleeding, pain or discomfort, allergic reaction to materials used in the device, and potential device malfunction.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have moderate heart condition symptoms.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion of approximately 4.5 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion of approximately 4.5 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Heart Failure Event Related Data will be assessed in all subjects through collection of reportable events and subsequent adjudication by the CEC.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment ArmExperimental Treatment1 Intervention
All study subjects belong to Treatment Arm, which is receiving investigational LUX-Dx ICM device.

Find a Location

Who is running the clinical trial?

Boston Scientific CorporationLead Sponsor
719 Previous Clinical Trials
932,545 Total Patients Enrolled
72 Trials studying Heart Failure
42,630 Patients Enrolled for Heart Failure
Scott Solomon, MDPrincipal InvestigatorBrigham and Women's Hospital
6 Previous Clinical Trials
19,727 Total Patients Enrolled
Elaine Wan, MDPrincipal InvestigatorColumbia University

Media Library

Investigational LUX-Dx ICM Implant (Diagnostic Sensor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04790344 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what capacity is enrollment open for this medical experiment?

"To effectively execute the trial, 435 volunteers who satisfy the prerequisites will be required. These participants may come from a few different medical centres including Sacred Heart Medical Center at Riverbend in Springfield, Oregon and Cardiovascular Associates of the Delaware Valley in Sewell, New jersey."

Answered by AI

Are there any open seats in this clinical study?

"The details available on clinicaltrials.gov signify that the recruiting process for this medical experiment is ongoing. It was first posted in March 2021 and underwent its most recent update in November 2022."

Answered by AI

How many locations can individuals obtain this trial?

"67 medical institutions are currently recruiting for this trial, such as Sacred Heart Medical Center at Riverbend in Springfield, Cardiovascular Associates of the Delaware Valley in Sewell, and WakeMed in Raleigh. Additionally there are 64 other participating locations."

Answered by AI

Who else is applying?

What state do they live in?
North Carolina
What site did they apply to?
WakeMed
Arrhythmia Research Group
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0
3+
~207 spots leftby May 2026